Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety, Tolerability, and Prophylactic Anti-Cytomegalovirus Activity of Maribavir [Camvia] in Recipients of Allogeneic Stem Cell Transplants.

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety, Tolerability, and Prophylactic Anti-Cytomegalovirus Activity of Maribavir [Camvia] in Recipients of Allogeneic Stem Cell Transplants.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maribavir (Primary)
  • Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
  • Focus Adverse reactions
  • Sponsors ViroPharma

Most Recent Events

  • 02 Jun 2008 Results published in Blood, 1 June 2008, previously presented at ASH 2006, Orlando, Florida, USA, 2006.
  • 31 Jan 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top